Mark Pykett, PhD, Chief Scientific Officer at PTC Therapeutics, provides an overview of his company, including its focus on rare diseases.

Mark leads the research initiatives of PTC. Before joining the company in August 2018, Mark held a number of executive positions, including president and CEO of Agilis Biotherapeutics, CEO of Navidea Biopharmaceuticals, and president and CEO of Alseres Pharmaceuticals, among others.